Evidence map›Paper›PMID 41209167›Full record

ArticleKidney medicine2025

Associations of Plasma and Urine Uromodulin With Kidney Disease Progression in Persons With Chronic Kidney Disease and Hypertension: The Systolic Blood Pressure Intervention Trial.

Jesse C Ikeme, Rebecca Scherzer, Pranav S Garimella, Stein I Hallan, Ronit Katz, Michelle M Estrella, Joachim H Ix, Michael G Shlipak

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Endocrine regulation of uromodulin in aging.Frontiers in endocrinology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jesse C IkemeKidney Health Research Collaborative, University of California, San Francisco and San Francisco Veterans Affairs Health Care System, San Francisco, CA.
Rebecca ScherzerKidney Health Research Collaborative, University of California, San Francisco and San Francisco Veterans Affairs Health Care System, San Francisco, CA.
Pranav S GarimellaDivision of Nephrology and Hypertension, Department of Medicine, University of California San Diego, San Diego, CA.
Stein I HallanDepartment of Nephrology, St Olav's Hospital, Trondheim, Norway and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Ronit KatzDepartment of Obstetrics and Gynecology, University of Washington, Seattle, WA.
Michelle M EstrellaKidney Health Research Collaborative, University of California, San Francisco and San Francisco Veterans Affairs Health Care System, San Francisco, CA.
Joachim H IxDivision of Nephrology and Hypertension, Department of Medicine, University of California San Diego, San Diego, CA.
Michael G ShlipakKidney Health Research Collaborative, University of California, San Francisco and San Francisco Veterans Affairs Health Care System, San Francisco, CA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale & Objective: Uromodulin (UMOD) is a kidney tubule biomarker that can be measured in blood and urine and may help identify persons with chronic kidney disease (CKD) at greater risk of progression. Whether blood or urine UMOD is more strongly associated with CKD progression is unknown. Study Design: This was a secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT), in which an intensive systolic blood pressure target reduced risk of cardiovascular events and mortality. Setting & Population: A total of 2,302 SPRINT participants with an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m Exposures: Plasma and urine UMOD measured at baseline. Outcomes: Acute kidney injury, 30% decline in eGFR, end-stage kidney disease, and annualized percentage change in eGFR. Analytical Approach: Cox proportional hazards (acute kidney injury, 30% eGFR decline, and end-stage kidney disease) and linear mixed models (annual percent eGFR change) were adjusted for baseline characteristics, including eGFR and albuminuria. Results: Among included participants, mean age was 73 years, 41% were female, and median eGFR was 50 (interquartile range: 40-57) mL/min/1.73 m Conclusions: Among persons with hypertension and CKD, plasma UMOD levels were associated with slower decline in eGFR and reduced risk of 30% eGFR decline after adjustment for demographic and clinical characteristics, whereas urine UMOD levels were not. When evaluating risk of kidney endpoints, plasma rather than urine may be the preferable specimen for UMOD measurement.

Indexed as

acute kidney injurychronic kidney diseaseend-stage kidney diseasehypertensionuromodulin

Identifiers

PMID41209167
PMCPMC12595371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.